New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

Updated, longer-term results from the COMMANDS trial show a promising trend toward improved overall survival with ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...

Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.

On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a ...

Multiple myeloma is considered incurable, but a third of patients in a clinical trial have lived without detectable cancer for years, after facing certain death ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

At the 2025 ASCO (American Society of Clinical Oncology) Annual Meeting, Dr. Armenian presented findings from the session ...

ASCO Data Shows New Therapy Keeps Myeloma Patients in Remission for 5+ Years. Here's what you need to know about the ...